Globus Medical Inc. (GMED)

NYSE: GMED · Real-Time Price · USD

71.14

-0.63 (-0.88%)

At close: May 01, 2025, 12:09 PM

-0.88% (1D)

Bid	71.11
Market Cap	11.38B
Revenue (ttm)	2.52B
Net Income (ttm)	102.98M
EPS (ttm)	0.75
PE Ratio (ttm)	94.85
Forward PE	18.14
Analyst	Buy

Ask	71.21
Volume	132,842
Avg. Volume (20D)	1,285,554
Open	72.05
Previous Close	71.77
Day's Range	71.06 - 72.11
52-Week Range	50.00 - 94.93
Beta	1.29

About GMED

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion p...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Aug 3, 2012

Employees 5,300

Stock Exchange NYSE

Ticker Symbol GMED

Website https://www.globusmedical.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for GMED stock is "Buy." The 12-month stock price forecast is $97, which is an increase of 36.36% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+9.43%

Globus Medical shares are trading higher after the... Unlock content with Pro Subscription

5 months ago

+1.15%

Globus Medical shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

News

5 hours ago · zacks.com

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Just now · zacks.com

4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates

MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.

1 week ago · zacks.com

Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 week ago · zacks.com

Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?

Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.

1 week ago · zacks.com

Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago · zacks.com

International Growth Drives GMED Stock Amid Fierce Competition

Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

3 weeks ago · zacks.com

GMED Stock May Benefit Following the Acquisition of Nevro

Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.

1 month ago · businesswire.com

NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro...